Table 1.

Clinical characteristics of the pilot cohort (n=104)

CharacteristicAll Participants, n (%)Successfully Recontacted, n (%)Unsuccessfully Recontacted, n (%)
Number of participants1046440
Age at time of study entry, yr
 0–213 (3)1 (2)2 (5)
 22–4974 (71)45 (70)29 (73)
 ≥5027 (26)18 (28)9 (23)
 Median (IQR)38 (28–51)40 (29–52)35 (28–48)
Sex
 Female40 (39)32 (50)8 (20)
Race/ethnicity
 White60 (58)45 (70)15 (38)
 Hispanic/Latino22 (21)10 (16)12 (30)
 Black9 (9)3 (5)6 (15)
 Asian12 (12)6 (9)6 (15)
 Other/unspecified1 (1)01 (3)
Study entry yr
 Before 20107 (7)2 (3)5 (13)
 2010–201418 (17)13 (20)5 (13)
 2015–201979 (76)49 (77)30 (75)
Time from enrollment to recontact attempt, yr
 Median (IQR)2.9 (1.9–3.8)2.4 (1.7–3.7)3.3 (2.8–4.1)
Insurance category
 Private78 (75)53 (83)25 (63)
 Public (including Medicare, Medicaid)26 (25)11 (17)15 (38)
Reached kidney failurea42 (40)21 (33)21 (53)
Positive family history for kidney disease66 (64)43 (67)23 (58)
Clinical diagnosis
 Congenital or cystic kidney disease9 (9)6 (9)3 (8)
 Glomerulopathy54 (52)33 (52)21 (53)
 Diabetic nephropathy3 (3)1 (2)2 (5)
 Tubulointerstitial disease11 (11)8 (13)3 (8)
 Nephropathy of unknown origin26 (25)15 (23)11 (28)
 Other1 (1)1 (2)0
  • IQR, interquartile range.

  • Percentages do not all sum to 100% due to rounding.

  • a Kidney failure includes patients on KRT and kidney transplant recipients.